Masimo
MASI
$178.63
-0.04%
Masimo Corporation is a medical technology company that develops, manufactures, and markets noninvasive patient monitoring technologies, hospital automation solutions, and consumer health products, operating within the Medical Instruments & Supplies industry. The company is a recognized leader in pulse oximetry and advanced monitoring, with a distinct identity built on proprietary signal processing technologies like Masimo SET®. The current investor narrative is overwhelmingly dominated by its pending acquisition by Danaher Corporation, a blockbuster deal that has catalyzed a massive re-rating of the stock and represents a premium exit for shareholders after a period of operational challenges and stock underperformance.…
MASI
Masimo
$178.63
Related headlines
Investment Opinion: Should I buy MASI Today?
Rating: Hold. The investment thesis is purely a merger arbitrage play with limited upside and asymmetric downside risk, making it unsuitable for a traditional Buy rating for most investors.
Supporting evidence for this Hold rating includes the stock trading at $178.39, just $0.61 (0.3%) below its 52-week high and the implied acquisition price ceiling. The 25.58% surge over three months has captured the vast majority of the deal premium. While Q4 2025 showed strong profitability (16.6% net margin) and the forward P/E of 27.03x is not egregious for a medical technology company, these metrics are irrelevant if the deal completes, and they are too weak to support the current price if it fails. The lack of analyst price targets and the shift to neutral ratings by major firms like Raymond James and Wells Fargo confirm the arbitrage nature of the current holding.
The two biggest risks are deal break risk and time-to-close risk. This Hold would downgrade to a Sell if the stock price meaningfully exceeds $179.0 without a raised offer, indicating irrational speculation, or if credible news emerges of regulatory challenges. It would only upgrade to a Buy if the price fell significantly below the likely deal value (e.g., below $170) on unfounded fears, creating a compelling risk/reward. Relative to its pre-deal fundamentals, the stock is overvalued; relative to the acquisition price, it is fairly valued with no margin of safety.
Sign up to view all
MASI 12-Month Price Forecast
The 12-month outlook for MASI is a binary event centered on the Danaher acquisition. We assign a 75% probability to the bull case (successful deal) as the most likely outcome, given the strategic fit and Danaher's financial capacity. However, the current price offers negligible upside to the deal price, creating a poor risk/reward profile for new money. The stance is Neutral with High confidence because the outcome is largely knowable—the stock will converge to the deal price or collapse—and the current price accurately reflects this. We would become Bearish only if deal break risk materially increases, and Bullish only if the price disconnects significantly below the deal value.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Masimo's 12-month outlook, with a consensus price target around $232.22 and implied upside of +30.0% versus the current price.
Average Target
$232.22
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$143 - $232
Analyst target range
Analyst coverage data is insufficient for deriving a meaningful consensus, as the provided data indicates only one analyst providing estimates for revenue and EPS, with no traditional price targets or buy/hold/sell ratings shown. This limited coverage is atypical for a company of Masimo's size and suggests that, following the acquisition announcement, many analysts have suspended traditional ratings and price targets, as the stock's fate is now tied to deal completion rather than operational performance. The institutional ratings history shows a clear pattern of downgrades coinciding with the acquisition news, with Raymond James, Wells Fargo, and BTIG all moving to neutral or market perform ratings in February and March 2026 from prior bullish stances, signaling that the arbitrage play is now the primary focus, with limited fundamental catalysts remaining. The wide dispersion in historical analyst views and the recent shift to neutral ratings underscore the high uncertainty that has now been resolved by the acquisition offer, making traditional price targets obsolete and leaving the deal premium as the key variable for shareholder returns.
Bulls vs Bears: MASI Investment Factors
The bullish case is overwhelmingly stronger, but it is entirely dependent on a single, non-operational catalyst: the successful completion of the Danaher acquisition. The bear points highlight the company's standalone operational weaknesses, including volatile revenue and negative trailing profitability, which justified the stock's underperformance prior to the deal announcement. The most critical tension in the investment debate is no longer about Masimo's fundamentals but about deal risk—specifically, the probability of regulatory approval and the final closing price versus the current market price, which leaves almost no room for error.
Bullish
- Premium Acquisition by Danaher: The pending acquisition by Danaher provides a definitive, high-probability exit for shareholders at a significant premium. The stock surged 25.58% over three months to trade at 99.7% of its 52-week high, reflecting the market's confidence in deal completion.
- The company demonstrated robust underlying profitability with Q4 2025 net income of $68.3 million and a net margin of 16.6%, a dramatic recovery from the -$100.4 million loss in Q3 2025. This showcases the core business's health when excluding one-time items.
- High and Stable Gross Margins: Masimo maintains a high-margin profile, with a Q4 2025 gross margin of 59.95% and a trailing gross margin of 61.9%. This structural profitability supports the valuation and the strategic rationale for Danaher's acquisition.
- Solid Balance Sheet and Liquidity: The company has a strong current ratio of 2.49 and moderate leverage with a debt-to-equity ratio of 0.78. It generated $60.5M in operating cash flow last quarter, providing financial stability during the acquisition process.
Bearish
- Volatile and Recently Negative Revenue: Q4 2025 revenue of $412.5M declined 31.3% YoY, highlighting significant top-line volatility. While partly due to a tough comparison, revenue has stabilized at a lower level than the anomalous $600.7M quarter in Q4 2024.
- Trailing Profitability Remains Negative: Despite a strong Q4, cumulative losses over the past twelve months result in a negative trailing P/E of -45.07 and a negative net margin of -9.9%. This underscores the operational challenges that preceded the acquisition offer.
- Limited Fundamental Upside Post-Deal: With the stock trading at $178.39, just $0.61 below its 52-week high of $179.0, nearly all acquisition premium appears priced in. Analyst coverage has largely been suspended, indicating the arbitrage play offers minimal standalone growth potential.
- High Valuation Multiples on Fundamentals: Standalone valuation metrics are stretched, with a forward P/E of 27.03x and a Price/Sales ratio of 4.47x. These multiples are not justified by recent volatile growth and are solely supported by the acquisition price.
MASI Technical Analysis
The stock is in a powerful, sustained uptrend, having surged 25.58% over the past three months and 17.25% over the past year, decisively breaking out of a prior trading range. As of the latest close at $178.39, the price is trading at approximately 99.7% of its 52-week high of $179.0, indicating it is testing a critical resistance level at the absolute peak of its range; this positioning near all-time highs reflects extreme bullish momentum driven by M&A speculation but also suggests potential overextension. Recent momentum is exceptionally strong and accelerating, with a 1-month gain of 1.32% and a 3-month surge of 25.58%, which starkly contrasts with the S&P 500's 2.67% 3-month return, highlighting a massive 22.91 percentage points of relative strength over that period. The price action shows a definitive structural shift, with the stock gapping up from around $130 in mid-February 2026 to the $175-$178 plateau and consolidating there with very low volatility, signaling the market has priced in the acquisition's high probability of completion. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $179.0 and support now established at the pre-announcement level near $130 (the 52-week low is $125.94). A sustained breakout above $179 would signal further bullish conviction, while a breakdown below the $175 consolidation zone could indicate deal uncertainty; the stock's beta of 1.202 indicates it is typically 20% more volatile than the market, but recent price action has been dominated by idiosyncratic M&A news rather than systematic factors.
Beta
1.20
1.20x market volatility
Max Drawdown
-25.9%
Largest decline past year
52-Week Range
$126-$179
Price range past year
Annual Return
+9.8%
Cumulative gain past year
| Period | MASI Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +8.7% |
| 3m | +26.3% | +3.6% |
| 6m | +20.9% | +5.4% |
| 1y | +9.8% | +30.6% |
| ytd | +40.2% | +4.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MASI Fundamental Analysis
Revenue growth has been volatile and recently negative, with Q4 2025 revenue of $412.5 million representing a significant 31.3% year-over-year decline, though this is partly due to the difficult comparison against a prior-year quarter that included a large, non-recurring contract. The multi-quarter trend shows revenue stabilizing in the $370-$412 million range over the past year, following the anomalous $600.7 million quarter in Q4 2024, indicating a return to a more normalized, albeit currently soft, growth trajectory as the company integrates its Sound United consumer acquisition. Profitability has been inconsistent but showed a strong rebound in the latest quarter, with Q4 2025 net income of $68.3 million and a net margin of 16.6%, a dramatic improvement from the net loss of -$100.4 million in Q3 2025. Gross margin remains robust at 59.95% for Q4 2025, consistent with the company's high-margin technology profile, and the operating margin was a healthy 20.3%, demonstrating the underlying profitability of the core healthcare business when excluding one-time charges and acquisition-related costs. The balance sheet and cash flow position is adequate, with a current ratio of 2.49 indicating good short-term liquidity, a debt-to-equity ratio of 0.78 reflecting moderate leverage, and trailing twelve-month free cash flow of $195.8 million. The company generated $60.5 million in operating cash flow in Q4 2025, and while it has engaged in significant stock repurchases ($186.7 million in the quarter), its financial health is sufficient to support operations, though the pending acquisition by Danaher makes standalone financial metrics largely moot for future assessment.
Quarterly Revenue
$412500000.0B
2026-01
Revenue YoY Growth
-0.31%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$195800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MASI Overvalued?
Given the company's positive net income in the most recent quarter, the primary valuation metric is the P/E ratio. The trailing P/E is negative at -45.07 due to cumulative losses over the past twelve months, but the forward P/E of 27.03 is meaningful and reflects market expectations of normalized future profitability, with the gap indicating the market is anticipating a significant earnings recovery. Compared to industry averages, Masimo's forward P/E of 27.03x and Price/Sales ratio of 4.47x are not directly comparable in a vacuum due to the pending acquisition, but historically, these multiples would be evaluated against medical device peers; the current valuation is entirely anchored to the acquisition takeout price rather than standalone fundamentals. In historical context, the stock's current Price/Sales ratio of 4.47x sits well below its own historical peaks seen in 2021 (often above 40x) but above the lows seen during its operational struggles in 2023-2024, indicating the market has re-rated the stock to a level that reflects the certainty of a premium acquisition, leaving little room for further multiple expansion outside of deal completion.
PE
-45.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -19x~181x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are currently secondary but notable. Masimo's revenue declined 31.3% YoY in Q4 2025, demonstrating high volatility and dependence on large, non-recurring contracts. While profitability rebounded sharply last quarter, the trailing twelve-month net margin remains negative at -9.9%, and the company has a history of significant quarterly earnings swings, as seen in the -$100.4M loss in Q3 2025. The debt-to-equity ratio of 0.78 indicates moderate leverage, but the primary financial risk is that the acquisition fails, leaving the company to navigate its volatile earnings trajectory alone.
Market & Competitive Risks are dominated by M&A execution risk. The stock's valuation (forward P/E of 27.03x) is entirely tied to the acquisition premium. Any regulatory hurdle, shareholder dissent, or macro shift affecting Danaher's financing could cause the deal to break, leading to severe multiple compression. The stock's beta of 1.202 suggests it is typically 20% more volatile than the market, and in a deal-break scenario, this volatility would likely amplify on the downside as the stock re-prices to its pre-deal fundamental valuation.
Worst-Case Scenario involves the Danaher acquisition falling through due to regulatory intervention or a material adverse change. In this event, the stock would likely collapse back to its pre-announcement trading range, centered around $130, and potentially test its 52-week low of $125.94. This represents a downside of approximately -29% to -30% from the current price of $178.39. The chain of events would likely trigger massive selling, analyst downgrades, and a re-focus on the company's inconsistent revenue and earnings, leading to a prolonged period of underperformance.
FAQ
The key risks are: 1) Deal Break Risk (Severe): Regulatory rejection or financing failure could cause the stock to plummet -30% to its pre-deal level near $130. 2) Time-to-Close Risk (Moderate): A prolonged regulatory review ties up capital for minimal return. 3) Fundamental Deterioration Risk (Low): A catastrophic earnings miss could invoke a Material Adverse Change clause, though Q4 2025's $68.3M profit provides a buffer. 4) Market Risk (Moderate): The stock's beta of 1.202 means it could be volatile if the deal fails and it reverts to trading on fundamentals.
The forecast is scenario-based due to the pending acquisition. The Bull Case (75% probability) sees the stock reaching $179-$185 upon deal closure. The Base Case (20% probability) envisions a completed deal at the current price level, with a target range of $130-$150 if delayed. The Bear Case (5% probability) forecasts a collapse to $110-$130 if the deal fails. The most likely scenario is the Bull Case, predicated on the high likelihood of regulatory approval for Danaher's acquisition. The weighted average expectation points to a price near the current level with minimal upside.
MASI's valuation is bifurcated. Relative to its standalone fundamentals—volatile revenue, negative trailing profitability, and a forward P/E of 27.03x—the stock is overvalued. However, relative to the pending acquisition by Danaher, the stock is fairly valued, as the market price has converged to the deal price. The Price/Sales ratio of 4.47x and EV/EBITDA of 21.0x are not meaningful benchmarks currently. The valuation implies the market assigns a very high probability (reflected in the 75% bull case) to the deal's successful completion, leaving no discount for uncertainty.
MASI is not a good stock to buy for traditional investors seeking growth or value. It is a pure merger arbitrage play. The stock trades at $178.39, just $0.61 below its 52-week high, implying less than 0.5% upside to the presumed deal price. The downside in a deal-break scenario is approximately -30% to the $125-$130 range. This asymmetric risk/reward profile makes it a suitable hold for existing shareholders awaiting the deal close, but a poor buy for new capital. It is only a 'good buy' for specialized arbitrageurs who can accurately assess and hedge the deal break risk.
MASI is exclusively suitable for a short-term, event-driven investment horizon tied to the acquisition closing, expected within 6-12 months. It is not a long-term hold. The company's volatile revenue (Q4 2025 down 31.3% YoY) and history of earnings inconsistency make it an unattractive standalone business for long-term investors. The stock's fate is now decoupled from its long-term fundamentals. The suggested minimum holding period is zero days for new buyers; existing shareholders should hold only until the deal closes or until a better risk-adjusted opportunity arises.